ema semaglutide safety committee to review link between and rare eye condition The weight loss drug Ozempic

In the STEP 1 clinical trial, participants on semaglutide lost an average of 14.9% of their body weight over 68 weeks, and 86% lost at least 5%

Influence of cortisol/DHEA ratio at presentation on subsequent rates of disappointing life events and persistent major depression

Appetite changes may begin within days to weeks

I.V., Intravenous

Patients taking Ozempic may experience disruption to normal digestive processes due to delayed gastric emptying and altered gut transit time

Both Novo and Lilly readily acknowledge they are unable to keep up and while a range of competitors from startups to pharma titans are rushing to get their own products to market, it is still going to be years until these products make it and there is no guarantee they will equal or trump the incumbents